Weekly epistaxis duration as an indicator of epistaxis severity in hereditary hemorrhagic telangiectasia—Preliminary results from a randomized controlled trial

OBJECTIVES: There is great interest in developing and studying novel therapies for epistaxis in hereditary hemorrhagic telangiectasia (HHT) given its associated morbidity and impact on patients' quality of life. Several recent randomized controlled trials (RCTs) have been negative, likely attri...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Vincent, Lee, John M., Vozoris, Nicholas T., Faughnan, Marie E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
ALLERGY, RHINOLOGY, AND IMMUNOLOGY
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8223446/
https://www.ncbi.nlm.nih.gov/pubmed/34195356
http://dx.doi.org/10.1002/lio2.561

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8223446/
https://www.ncbi.nlm.nih.gov/pubmed/34195356
http://dx.doi.org/10.1002/lio2.561

Ejemplares similares